Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT05891171
Adenocarcinoma, Adnexal Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT Number: NCT05347342
To improve upon the non-invasive detection of bladder cancer by further validating a multiplex ELISA assay directed at a bladder cancer-associated diagnostic signature in voided urine samples of patients with a high risk of developing bladder cancer.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Observational
Long Beach VA Healthcare System, Long Beach, California, United States
Environmental exposures, specifically tobacco smoke, increases the risk of many cancers, including bladder cancer. To date, there are no diagnostics capable of detecting bladder cancer early, that is prior to clinical presentation. Because of this severe limitation, nearly 30% of patients initially present with stage 2 and higher bladder cancer. Stage 2 bladder cancer has a 5-year survival of 50%, while stage 3/4 have a 5-year survival of <20%. Ideally, bladder cancer would be preventable. Unfortunate, this has not come to fruition. If these stage 2-4 bladder cancer cases could be detected at Stage 1 (5-yr survival >94%), then its possible to see an improvement in bladder cancer survival rates (21-23).
in this study, a urine-based diagnostic that possesses the potential to accurately identify patients who harbor bladder cancer prior to clinical manifestation will be tested.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Participants must be:
Exclusion criteria
Participants must not have:
Time frame: 5 years
Ability to recruit
Time frame: 5 years
Performance of multiplex test in this study
Time frame: 5 years
Development of a risk calculator
Cedars-Sinai Medical Center
Other
A Novel Multiplex Immunoassay for the Early Detection of Bladder Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05891171
Adenocarcinoma, Adnexal Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT07735858
Bladder Cancer, Female Urogenital Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT03693014
Bladder Cancer, Female Urogenital Diseases
Hartford, Connecticut, United States
View Trial DetailsNCT03915678
Bladder Cancer, Breast Diseases
Bordeaux, France
View Trial Details